Q-3039 — Mr. Julian (New Westminster—Burnaby) — With regard to federal funding to non-governmental organizations, broken down by department, agency and fiscal year since January 1, 2006: (a) has (i) the Canadian Independent Medical Clinics Association, (ii) Advocates for Choice in Healthcare, (iii) Innovative Medicines Canada, (iv) the Canadian Health Policy Institute, (v) the Montreal Economic Institute, received federal funding; and (b) how much federal funding, if any, was received by each organization listed in (a)? — Sessional Paper No. 8555-441-3039.

Q-3040 — Mr. Patzer (Cypress Hills—Grasslands) — With regard to the government’s $700 million loan to Air Transat announced in 2021: (a) what is the loan repayment schedule for the (i) principal owed, (ii) interest owed; (b) did the government exercise the right to purchase 13 million shares, and, if so, (i) on what date were they purchased, (ii) what was the cost per share; and (c) what have been the results of the annual job monitoring done on Air Transat for each year since the loan was issued, overall and for each job requirement that was a part of the condition of the government loan? — Sessional Paper No. 8555-441-3040.

Q-3041 — Mr. Patzer (Cypress Hills—Grasslands) — With regard to government dealings with Telesat, since November 4, 2015: (a) what are the details of all loans, grants, or other financial contributions that the government has provided to Telesat, including, for each, the (i) date, (ii) amount, (iii) type of contribution (loan, non-repayable grant, etc.), (iv) repayment terms, if applicable, (v) amount repaid to date, (vi) purpose, (vii) total houses connected to broadband resulting from the contribution; (b) what are the details of all contracts the government has with Telesat, or its subsidiaries, including, for each, the (i) date, (ii) amount, (iii) vendor, (iv) description of goods or services provided, (v) manner in which the contract was awarded (sole-sourced or competitive bid); (c) for each contract in (b) involving consulting services, what was the topic consulted on and what is the summary of any reports or recommendations provided to the government as part of the consulting contract; and (d) did any of the financial contributions in (a) include executive compensation restrictions and, if so, which contributions and what were the restrictions? — Sessional Paper No. 8555-441-3041.

Q-3042 — Mr. Barrett (Leeds—Grenville—Thousand Islands and Rideau Lakes) — With regard to all types of standby pay for Government of Canada employees since January 1, 2016, broken down by year: (a) what is the total cost of standby pay, broken down by department, agency, or other government entity; (b) how many employees had annual standby payments over $5,000 in each given year, broken down by department, agency, or other government entity; and (c) what was the single highest annual standby payment for an individual employee in each given year, broken down by department, agency, or other government entity? — Sessional Paper No. 8555-441-3042.

Q-3043 — Mr. Chambers (Simcoe North) — With regard to transcriptions or transcripts procured by the government since January 1, 2023, and broken down by department or agency: (a) what is the (i) date of the proceeding or event, (ii) location of the proceeding or event, (iii) description or summary of the proceeding or event, (iv) main participants speaking at the proceeding or event, (v) subject matter of the proceeding or event, for each transcription prepared in this period; (b) what was the cost of each transcription in (a); (c) who requested each transcription in (a) be prepared; and (d) what was the total amount spent on transcriptions or transcripts, broken down by year? — Sessional Paper No. 8555-441-3043.

Q-3044 — Mr. Leslie (Portage—Lisgar) — With regard to the Firearms Buyback Program: what are the details of all contracts related to the program entered into by the government, including any relevant government entity, such as the RCMP, including, for each, the (i) date, (ii) amount, (iii) vendor, (iv) description of the goods or services, (v) manner in which the contract was awarded (sole-sourced or competitive bid)? — Sessional Paper No. 8555-441-3044.

Q-3045 — Ms. Duncan (Etobicoke North) — With regard to performance-enhancing drugs (PEDs) in international sport and in Canada up to 1990: (a) what specific actions did Sport Canada (SC) take to combat the use of PEDs after (i) the International Olympic Committee’s (IOC) establishment of the Medical Commission in 1967, (ii) the Council of Europe’s resolution on drug abuse in sport in 1967, (iii) testing for stimulants and narcotics at the 1968 Grenoble Olympic Games and Mexico City Olympic Games, (iv) the first large-scale drug testing at the 1972 Munich Olympic Games, (v) the International Association of Athletics Federations’ (IAAF) and IOC Medical Commission’s ban on the use of anabolic steroids in 1974, (vi) a positive test by a Canadian at the 1975 Pan American Games in Mexico City, (vii) the Sport Medicine Council of Canada’s establishment in 1978, (viii) two disqualifications of Canadians at the 1983 Pan American Games in Caracas, (ix) the acceptance of the European Anti-Doping Charter of the Council of Europe’s Committee of Sports Ministers in 1984; (b) what specific actions did SC take to combat the use of PEDs after anti-doping legislation was enacted in (i) Belgium and France (1965), (ii) Ireland (1966), (iii) Italy and Turkey (1971), (iv) Greece (1976), (v) Portugal (1979); (c) in what year did Canada introduce an anti-doping policy; (d) why were only 15% of specimens at the 1976 Montreal Olympics tested for anabolic steroids; (e) in what year were PEDs first identified in any Canadian sport, and what (i) was the specific sport, (ii) were all the drugs reported to be used at that time; (f) what actions have been taken by SC on PEDs from its first action through to 1990, and on what date was each action taken; (g) what specific actions did SC take to address steroid use in sport after the editor of Track and Field News called anabolic steroids the “breakfast of champions” in 1969; (h) what specific action did SC take in 1976 to prevent the use of PEDs at the Montreal Olympics and Toronto Paralympics; (i) what specific actions did SC take to address steroid use in sport after the first edition of The Underground Steroid Handbook appeared in 1981, and what action, if any, did SC take to address the use of human growth hormone in sport, which was included in the handbook, before randomized, double-blind, controlled trials were published; (j) what specific actions did SC take to address steroid use in sport after the Sport Medicine Council of Canada surveyed 1,500 athletes, coaches, and medical and para-medical practitioners about doping in 1982 and found that “fewer than five percent of athletes” stated they used or had previously used PEDs; (k) what specific actions did SC take to address steroid use in sport after the publication of “The Practical Use of Anabolic Steroids with Athletes” in 1982; (l) in what year did testing for PEDs begin at the Canada Summer Games, how did SC decide what sports to test, what specific sports were tested at each Games since testing began until 1990, and what PEDs were tested for at each Games since testing began until 1990; (m) in what year did testing for PEDs begin at the Canada Winter Games, how did SC decide which sports to test, what specific sports were tested at each Games since testing began until 1990, and what PEDs were tested for at each Games since testing began until 1990; (n) in what year did the Canadian Olympic Committee first act to address PEDs, what specific actions did it take, and, for each action, on what date was it taken; (o) in what year did the Canadian Paralympic Committee first act to address PEDs, what specific actions did it take, and, for each action, on what date was it taken; (p) in what year did each national sport organization in Canada (i) begin testing for PEDs at competitions, (ii) begin announced testing for PEDs between competitions, (iii) begin unannounced testing for PEDs between competitions; (q) in five-year increments from 1970 to 1990, how many athletes were found to have used PEDs in Canada, broken down by sport, and what specific PEDs were being used, broken down by sport; (r) in five-year increments from 1970 to 1990, and for each identified PED, was the drug approved for veterinary use in Canada, what clinical trials did the drug pass for use in humans, was the drug approved for human use in Canada, for what specific medical use was the drug approved in Canada, what specific medical dosages were approved in Canada, was off-label use of the drug approved in Canada, what side-effects, if any, did the drug have, and what long-term impacts, if any, might the drug have had; (s) what are the details of all Olympic and Paralympic team physicians from 1968 to 1988, including, for each, (i) the dates they served, (ii) who, if anybody, raised concerns about PED use among athletes to SC and the date of the report to SC; (t) what investigation, if any, has SC undertaken to look at health impacts of anabolic steroids when (i) doses used were much higher than the recommended doses, (ii) there was simultaneous use of oral and injectable steroids, (iii) they were possibly used with human growth hormone; (u) what investigation, if any, has SC undertaken to look at morbidity and mortality of athletes who used PEDs during the 1970s and 1980s; (v) in five-year increments from 1970 to 1990, if an athlete was sanctioned in any way for use of a PED, what investigation, if any, was undertaken of any (i) coaches, (ii) medical personnel, (iii) other members of an athlete’s team, and what are the details of the investigation process; (w) in five-year increments from 1970 to 1990, how many athletes, broken down by sport, were sanctioned for any kind of drug infraction, and, for each identified infraction, were any (i) coaches, (ii) medical personnel, (iii) other members of an athlete’s team, sanctioned; and (x) in five-year increments from 1970 to 1990, how many (i) coaches, (ii) medical personnel, (iii) other members of an athlete’s team, were sanctioned? — Sessional Paper No. 8555-441-3045.

“provided that it be an instruction to the committee:

(a) that the following witnesses be ordered to appear before the committee, separately, for two hours each:

(i) the Minister of Innovation, Science and Industry,

(ii) the Clerk of the Privy Council,

(iii) the Privacy Commissioner of Canada, who respected the order of the House and deposited unredacted documents,

(iv) Paul MacKinnon, the former Deputy Secretary to the Cabinet (Governance),

(v) the Auditor General of Canada,

(vi) the Commissioner of the Royal Canadian Mounted Police,

(vii) the Deputy Minister of Innovation, Science and Economic Development Canada,

(viii) the Law Clerk and Parliamentary Counsel of the House of Commons,

(ix) the Acting President of Sustainable Development Technology Canada,

(x) a panel consisting of the Board of Sustainable Development Technology Canada; and

(b) that it report back to the House no later than the 30th sitting day following the adoption of this order.";

“, except that the order for the committee to report back to the House within 30 sitting days shall be discharged if the Speaker has sooner laid upon the table a notice from the Law Clerk and Parliamentary Counsel confirming that all government institutions have fully complied with the order adopted on June 10, 2024, by depositing all of their responsive records in an unredacted form”.

“the 12th report of the Standing Committee on Human Resources, Skills and Social Development and the Status of Persons with Disabilities, presented on Thursday, October 26, 2023, be not now concurred in, but that it be recommitted to the committee for further consideration, with a view to consider the role of financialized landlords on rising costs in Canada’s rental market, including how the use of algorithmic pricing tools is contributing to rent increases and how pervasive this practice is across the Canadian rental market.”.